HK1223823A1 - 使用溶瘤腺病毒治療腦癌 - Google Patents
使用溶瘤腺病毒治療腦癌Info
- Publication number
- HK1223823A1 HK1223823A1 HK16111923.1A HK16111923A HK1223823A1 HK 1223823 A1 HK1223823 A1 HK 1223823A1 HK 16111923 A HK16111923 A HK 16111923A HK 1223823 A1 HK1223823 A1 HK 1223823A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- brain cancer
- oncolytic adenovirus
- oncolytic
- adenovirus
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
- 230000000174 oncolytic effect Effects 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836230P | 2013-06-18 | 2013-06-18 | |
| PCT/US2014/042375 WO2014204814A1 (en) | 2013-06-18 | 2014-06-13 | Treatment of brain cancer with oncolytic adenovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1223823A1 true HK1223823A1 (zh) | 2017-08-11 |
Family
ID=51134434
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16111923.1A HK1223823A1 (zh) | 2013-06-18 | 2016-10-14 | 使用溶瘤腺病毒治療腦癌 |
| HK16114263A HK1225962A1 (zh) | 2013-06-18 | 2016-12-15 | 使用溶瘤腺病毒的腦癌治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16114263A HK1225962A1 (zh) | 2013-06-18 | 2016-12-15 | 使用溶瘤腺病毒的腦癌治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20160143967A1 (zh) |
| EP (1) | EP3010519B1 (zh) |
| JP (2) | JP6613231B2 (zh) |
| KR (1) | KR20160054456A (zh) |
| CN (1) | CN105722518A (zh) |
| AU (1) | AU2014281826B2 (zh) |
| CA (1) | CA2915973A1 (zh) |
| DK (1) | DK3010519T3 (zh) |
| ES (1) | ES2878549T3 (zh) |
| HK (2) | HK1223823A1 (zh) |
| IL (1) | IL243215B (zh) |
| PL (1) | PL3010519T3 (zh) |
| PT (1) | PT3010519T (zh) |
| RU (1) | RU2689553C2 (zh) |
| SG (2) | SG10201710528WA (zh) |
| WO (1) | WO2014204814A1 (zh) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104427992B (zh) | 2012-01-25 | 2017-12-19 | 德那翠丝有限公司 | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 |
| EP2809788B1 (en) | 2012-02-02 | 2019-09-04 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| WO2018085461A1 (en) * | 2016-11-01 | 2018-05-11 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| WO2018118967A1 (en) | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
| EP3624821A4 (en) * | 2017-05-19 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP3669893A1 (en) * | 2018-12-20 | 2020-06-24 | Universidad Autónoma de Madrid | Treatment of p53 mutated/modified cancer-forms with parvovirus |
| KR20220038485A (ko) | 2019-08-05 | 2022-03-28 | 메조블라스트 인터내셔널 에스에이알엘 | 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법 |
| US20230293590A1 (en) | 2020-08-10 | 2023-09-21 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| RU2759405C1 (ru) * | 2021-02-26 | 2021-11-12 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ адъювантной адаптивной стереотаксической лучевой терапии в лечении первичных злокачественных глиальных опухолей головного мозга |
| EP4329878A1 (en) * | 2021-04-26 | 2024-03-06 | Dnatrix, Inc. | Use of oncolytic adenovirus for the treatment of pediatric brain cancer |
| WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| JPH10507758A (ja) | 1994-10-19 | 1998-07-28 | ジェネティック セラピー，インコーポレイテッド | アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療 |
| PL186018B1 (pl) * | 1995-11-30 | 2003-09-30 | Regents Board Of | Sposoby i kompozycje do diagnozowania i leczenia nowotworu |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| ATE540686T1 (de) | 1999-05-12 | 2012-01-15 | Uab Research Foundation | Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen |
| US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
-
2014
- 2014-06-13 ES ES14736238T patent/ES2878549T3/es active Active
- 2014-06-13 SG SG10201710528WA patent/SG10201710528WA/en unknown
- 2014-06-13 KR KR1020167001256A patent/KR20160054456A/ko not_active IP Right Cessation
- 2014-06-13 CN CN201480045528.9A patent/CN105722518A/zh active Pending
- 2014-06-13 PT PT147362388T patent/PT3010519T/pt unknown
- 2014-06-13 US US14/899,360 patent/US20160143967A1/en not_active Abandoned
- 2014-06-13 PL PL14736238T patent/PL3010519T3/pl unknown
- 2014-06-13 DK DK14736238.8T patent/DK3010519T3/da active
- 2014-06-13 EP EP14736238.8A patent/EP3010519B1/en active Active
- 2014-06-13 RU RU2016101057A patent/RU2689553C2/ru not_active IP Right Cessation
- 2014-06-13 CA CA2915973A patent/CA2915973A1/en not_active Abandoned
- 2014-06-13 AU AU2014281826A patent/AU2014281826B2/en not_active Ceased
- 2014-06-13 WO PCT/US2014/042375 patent/WO2014204814A1/en active Application Filing
- 2014-06-13 JP JP2016521479A patent/JP6613231B2/ja active Active
- 2014-06-13 SG SG11201510430RA patent/SG11201510430RA/en unknown
-
2015
- 2015-12-17 IL IL24321515A patent/IL243215B/en active IP Right Grant
-
2016
- 2016-10-14 HK HK16111923.1A patent/HK1223823A1/zh unknown
- 2016-12-15 HK HK16114263A patent/HK1225962A1/zh unknown
-
2019
- 2019-11-01 JP JP2019199677A patent/JP6956159B2/ja active Active
-
2021
- 2021-03-05 US US17/193,511 patent/US20210213079A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2878549T3 (es) | 2021-11-19 |
| RU2016101057A (ru) | 2017-07-21 |
| JP6613231B2 (ja) | 2019-11-27 |
| JP6956159B2 (ja) | 2021-10-27 |
| PT3010519T (pt) | 2021-07-02 |
| JP2016523861A (ja) | 2016-08-12 |
| SG11201510430RA (en) | 2016-01-28 |
| CN105722518A (zh) | 2016-06-29 |
| RU2016101057A3 (zh) | 2018-03-19 |
| IL243215A0 (en) | 2016-02-29 |
| RU2689553C2 (ru) | 2019-05-28 |
| DK3010519T3 (en) | 2021-05-17 |
| US20210213079A1 (en) | 2021-07-15 |
| EP3010519B1 (en) | 2021-04-07 |
| EP3010519A1 (en) | 2016-04-27 |
| US20160143967A1 (en) | 2016-05-26 |
| AU2014281826B2 (en) | 2019-10-17 |
| HK1225962A1 (zh) | 2017-09-22 |
| PL3010519T3 (pl) | 2021-09-27 |
| SG10201710528WA (en) | 2018-01-30 |
| IL243215B (en) | 2019-10-31 |
| KR20160054456A (ko) | 2016-05-16 |
| WO2014204814A1 (en) | 2014-12-24 |
| CA2915973A1 (en) | 2014-12-24 |
| AU2014281826A1 (en) | 2016-01-21 |
| JP2020033373A (ja) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225962A1 (zh) | 使用溶瘤腺病毒的腦癌治療 | |
| ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
| HK1219231A1 (zh) | 治療兒童實體瘤的方法 | |
| HUE057061T2 (hu) | Kombinációs terápia rák kezelésére | |
| SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| HK1213817A1 (zh) | 治療癌症的方法 | |
| HK1219513A1 (zh) | 治療癌症的方法 | |
| HK1223547A1 (zh) | 癌症治療方法 | |
| GB201403083D0 (en) | Treatment of cancer | |
| HK1232118A1 (zh) | 癌症的治療 | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| EP3007712A4 (en) | Treatment of cancer | |
| GB201518731D0 (en) | Tumour Therapy | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201300546D0 (en) | Cancer Treatment | |
| SG10201802995SA (en) | Cancer treatment with combination of plinabulin and taxane | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer | |
| GB201308365D0 (en) | Tumour therapy |